CRISPR Fusion Silencing Targets Cancer's Hidden Seams

Researchers at the Peter MacCallum Cancer Centre have built a programmable CRISPR fusion silencing system that switches off cancer-driving gene fusions by locking onto the exact seam where two broken genes were stitched together. The approach, described in the journal Science Advances, treats that seam as a fingerprint that exists only in tumor cells. According to the team, hitting it could one day let doctors shut down the instructions driving a cancer without touching the healthy DNA around it.

Gene fusions happen when DNA snaps inside a cell and repairs itself badly, gluing part of one gene to part of another. The result is a garbled instruction set that can push a cell toward cancer. The paper notes that such fusions show up in about one in five cancers and act as the confirmed drivers in 16.5 percent of them. Two of the most notorious examples are BCR-ABL1, which appears in nearly every case of chronic myeloid leukemia, and EWSR1-FLI1, found in more than eighty-five percent of cases of Ewing's sarcoma, a rare cancer of bone and the surrounding soft tissue.

The new method aims at the breakpoint itself, the short stretch of code where the two genes meet. A guide sequence steers an RNA-cutting enzyme called Cas13b to that spot, and the enzyme slices up the fusion's message before the cell can read it. Because the breakpoint sequence does not occur in healthy cells, the cut should land only where it is wanted. In the proof-of-concept work, the researchers successfully silenced nine different fusion transcripts, including the one behind chronic myeloid leukemia.

Why the seam makes a better target

Older gene-editing approaches aim at DNA itself, which means a missed cut lands in the patient's own genome. CRISPR fusion silencing works one step downstream instead, on the RNA messages the fusions produce. The paper's first author, Wenxin Hu, describes the breakpoint as a unique molecular fingerprint that allows precise targeting, and adds that reprogramming the same CRISPR system to recognize different genetic drivers brings personalized treatment a step closer. Because the enzyme cuts RNA rather than DNA, the underlying genes stay intact.

That reprogrammability is the point. Gene fusions come in many flavors, and two patients with the same diagnosis can carry slightly different seams. Instead of building a new therapy for each one, the CRISPR fusion silencing approach would swap in a new guide sequence matched to the patient's own tumor. The study's senior researcher, Mohamad Fareh, said the long-term goal is programmable cancer medicines tailored to the genetic abnormalities driving each individual tumor, and that the study turns the genetic information doctors can already read from tumors into a new way of treating them.

The fusion work builds on earlier research from the same laboratory. In a 2024 study published in Nature Structural & Molecular Biology, Fareh and Hu showed that the same RNA-cutting CRISPR system could be tuned to destroy disease-causing RNA with high precision while leaving DNA untouched. The latest paper applies that lesson to the breakpoint problem, using CRISPR fusion silencing to target fusion messages across blood and solid tumors.

What still has to be proven

None of this has left the lab bench yet. The team demonstrated CRISPR fusion silencing in laboratory cell models, and it has not been tested in animals or in people. The open question is delivery: getting the CRISPR machinery into real tumors, and confirming it finds cancer cells while leaving healthy tissue alone. Those experiments come next, in more complex models. A failed delivery step has sunk more than one promising gene therapy, which is why the researchers treat it as the main test still ahead.

For now, the result is a design manual rather than a drug. The full study, titled "Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition," was published in Science Advances with DOI 10.1126/sciadv.ady0296. If CRISPR fusion silencing clears those hurdles, doctors could one day read a patient's fusion fingerprint from a biopsy and build the countermeasure to match.

MedicalXpress reported on the findings, which trace back to the Peter MacCallum Cancer Centre team led by Dr. Mohamad Fareh.